$13.250
+0.433 (+3.27%)Zum Schluss
AMWL-News
AMWL-Events
Adjusts FY26 EBITDA Loss Outlook to $7M-$9M
Consensus $202.33M. Raises FY26 adjusted EBITDA loss view to $7M-$9M from $12M-$16M.
Sees Q3 Adjusted EBITDA Loss of $3M-$5M
Sees Q3 adjusted EBITDA loss $3M-$5M.
Amwell Reports Q2 Revenue of $52.05M, Exceeding Expectations
Reports Q2 revenue $52.05M, consensus $49.88M. "The DHA's intent to make Amwell a prime contractor is a powerful endorsement of our platform and our people," said Ido Schoenberg, Chairman and CEO of Amwell. "With subscription revenue now approaching half our total revenue, independently validated behavioral clinical outcomes, no debt, and positive cash flows from operations projected for the fourth quarter this year, we have never been better positioned to lead the era of AI-powered care."
Sees Q1 Adjusted EBITDA in Range of ($7M)-($5M)
Sees Q1 adjusted EBITDA in the range of ($7M)-($5M).
Amwell Reports Q4 Revenue of $55.3M, Exceeds Expectations
Reports Q4 revenue $55.3M, consensus $52.71M. Total visits were 1.0M. "In 2025, we sharpened our focus on our Technology Enabled Care platform, which addresses clear and urgent unmet needs across Government, Payer, and Health System clients. Our infrastructure enables clients to effectively deploy Amwell's clinical programs alongside a growing ecosystem of third-party, AI-powered clinical programs - reducing costs, improving outcomes, and transforming the care experience. This focus allowed us to transform our cost base, elevate our revenue quality, and achieve strong market validation through numerous contract renewals and new client wins. Amwell is now well-positioned to reach our goal of cash flow breakeven in the fourth quarter of this year," said Dr. Ido Schoenberg, Chairman and CEO of Amwell.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.